Toxicities of targeted therapy and their management in kidney cancer

Giuseppe Di Lorenzo, Camillo Porta, Joaquim Bellmunt, Cora Sternberg, Ziya Kirkali, Michael Staehler, Steven Joniau, Francesco Montorsi, Carlo Buonerba

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Context: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and temsirolimus being successfully tested and approved in a short period of time. Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents. Objective: To describe toxic effects associated with targeted therapy of mRCC and their proper management on the basis of currently available evidence. Evidence acquisition: We conducted a systematic analysis of the literature on 15th October 2010 by performing a search of Medical Subject Headings (MeSH) on PubMed using the words sorafenib, sunitinib, bevacizumab, everolimus, pazopanib, or temsirolimus combined with the MeSH term kidney neoplasms. Consideration for inclusion was given to articles providing data concerning (1) incidence and grading and (2) management of targeted therapy-related toxic effects. A separate search was conducted on PubMed to retrieve meta-analyses using each drug name and the word meta-analysis. Evidence synthesis: Hypertension, fatigue, bone marrow toxicity, skin toxicity, and gastrointestinal side-effects are common with the six targeted agents. Everolimus and temsirolimus are associated with immunosuppression, metabolic alterations, and interstitial pneumonitis, while sunitinib is associated with hypothyroidism. Recommendations for treating these conditions usually follow those for the general population because of the lack of experimental data in this setting (eg, for management of sunitinib-induced hypertension). Conclusions: The treating oncologist should try to manage side-effects associated with targeted therapy using supportive and pharmacologic interventions. Severe toxicity requires external specialist consultation and treatment suspension and/or dose reduction. Experimental data about the management of targeted therapy-related toxicity in mRCC is lacking and required in this setting.

Original languageEnglish
Pages (from-to)526-540
Number of pages15
JournalEuropean Urology
Volume59
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Medical Subject Headings
Poisons
PubMed
Meta-Analysis
Therapeutics
Hypertension
Interstitial Lung Diseases
Biological Factors
Hypothyroidism
Immunosuppression
Names
Fatigue
Suspensions
Referral and Consultation
Bone Marrow
Skin
sunitinib
Incidence

Keywords

  • Metastatic renal cell cancer
  • Targeted agents
  • Toxicity

ASJC Scopus subject areas

  • Urology

Cite this

Di Lorenzo, G., Porta, C., Bellmunt, J., Sternberg, C., Kirkali, Z., Staehler, M., ... Buonerba, C. (2011). Toxicities of targeted therapy and their management in kidney cancer. European Urology, 59(4), 526-540. https://doi.org/10.1016/j.eururo.2011.01.002

Toxicities of targeted therapy and their management in kidney cancer. / Di Lorenzo, Giuseppe; Porta, Camillo; Bellmunt, Joaquim; Sternberg, Cora; Kirkali, Ziya; Staehler, Michael; Joniau, Steven; Montorsi, Francesco; Buonerba, Carlo.

In: European Urology, Vol. 59, No. 4, 04.2011, p. 526-540.

Research output: Contribution to journalArticle

Di Lorenzo, G, Porta, C, Bellmunt, J, Sternberg, C, Kirkali, Z, Staehler, M, Joniau, S, Montorsi, F & Buonerba, C 2011, 'Toxicities of targeted therapy and their management in kidney cancer', European Urology, vol. 59, no. 4, pp. 526-540. https://doi.org/10.1016/j.eururo.2011.01.002
Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M et al. Toxicities of targeted therapy and their management in kidney cancer. European Urology. 2011 Apr;59(4):526-540. https://doi.org/10.1016/j.eururo.2011.01.002
Di Lorenzo, Giuseppe ; Porta, Camillo ; Bellmunt, Joaquim ; Sternberg, Cora ; Kirkali, Ziya ; Staehler, Michael ; Joniau, Steven ; Montorsi, Francesco ; Buonerba, Carlo. / Toxicities of targeted therapy and their management in kidney cancer. In: European Urology. 2011 ; Vol. 59, No. 4. pp. 526-540.
@article{9f93584e1c474090b643147bf63d4ec2,
title = "Toxicities of targeted therapy and their management in kidney cancer",
abstract = "Context: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and temsirolimus being successfully tested and approved in a short period of time. Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents. Objective: To describe toxic effects associated with targeted therapy of mRCC and their proper management on the basis of currently available evidence. Evidence acquisition: We conducted a systematic analysis of the literature on 15th October 2010 by performing a search of Medical Subject Headings (MeSH) on PubMed using the words sorafenib, sunitinib, bevacizumab, everolimus, pazopanib, or temsirolimus combined with the MeSH term kidney neoplasms. Consideration for inclusion was given to articles providing data concerning (1) incidence and grading and (2) management of targeted therapy-related toxic effects. A separate search was conducted on PubMed to retrieve meta-analyses using each drug name and the word meta-analysis. Evidence synthesis: Hypertension, fatigue, bone marrow toxicity, skin toxicity, and gastrointestinal side-effects are common with the six targeted agents. Everolimus and temsirolimus are associated with immunosuppression, metabolic alterations, and interstitial pneumonitis, while sunitinib is associated with hypothyroidism. Recommendations for treating these conditions usually follow those for the general population because of the lack of experimental data in this setting (eg, for management of sunitinib-induced hypertension). Conclusions: The treating oncologist should try to manage side-effects associated with targeted therapy using supportive and pharmacologic interventions. Severe toxicity requires external specialist consultation and treatment suspension and/or dose reduction. Experimental data about the management of targeted therapy-related toxicity in mRCC is lacking and required in this setting.",
keywords = "Metastatic renal cell cancer, Targeted agents, Toxicity",
author = "{Di Lorenzo}, Giuseppe and Camillo Porta and Joaquim Bellmunt and Cora Sternberg and Ziya Kirkali and Michael Staehler and Steven Joniau and Francesco Montorsi and Carlo Buonerba",
year = "2011",
month = "4",
doi = "10.1016/j.eururo.2011.01.002",
language = "English",
volume = "59",
pages = "526--540",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "4",

}

TY - JOUR

T1 - Toxicities of targeted therapy and their management in kidney cancer

AU - Di Lorenzo, Giuseppe

AU - Porta, Camillo

AU - Bellmunt, Joaquim

AU - Sternberg, Cora

AU - Kirkali, Ziya

AU - Staehler, Michael

AU - Joniau, Steven

AU - Montorsi, Francesco

AU - Buonerba, Carlo

PY - 2011/4

Y1 - 2011/4

N2 - Context: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and temsirolimus being successfully tested and approved in a short period of time. Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents. Objective: To describe toxic effects associated with targeted therapy of mRCC and their proper management on the basis of currently available evidence. Evidence acquisition: We conducted a systematic analysis of the literature on 15th October 2010 by performing a search of Medical Subject Headings (MeSH) on PubMed using the words sorafenib, sunitinib, bevacizumab, everolimus, pazopanib, or temsirolimus combined with the MeSH term kidney neoplasms. Consideration for inclusion was given to articles providing data concerning (1) incidence and grading and (2) management of targeted therapy-related toxic effects. A separate search was conducted on PubMed to retrieve meta-analyses using each drug name and the word meta-analysis. Evidence synthesis: Hypertension, fatigue, bone marrow toxicity, skin toxicity, and gastrointestinal side-effects are common with the six targeted agents. Everolimus and temsirolimus are associated with immunosuppression, metabolic alterations, and interstitial pneumonitis, while sunitinib is associated with hypothyroidism. Recommendations for treating these conditions usually follow those for the general population because of the lack of experimental data in this setting (eg, for management of sunitinib-induced hypertension). Conclusions: The treating oncologist should try to manage side-effects associated with targeted therapy using supportive and pharmacologic interventions. Severe toxicity requires external specialist consultation and treatment suspension and/or dose reduction. Experimental data about the management of targeted therapy-related toxicity in mRCC is lacking and required in this setting.

AB - Context: The therapeutic scenario for metastatic renal cell carcinoma (mRCC) has been evolving rapidly, with sunitinib, sorafenib, bevacizumab, everolimus, pazopanib, and temsirolimus being successfully tested and approved in a short period of time. Oncologists must be familiar with the management of toxicity that these biologic agents cause, as such toxicity is different from that of conventional chemotherapeutic agents. Objective: To describe toxic effects associated with targeted therapy of mRCC and their proper management on the basis of currently available evidence. Evidence acquisition: We conducted a systematic analysis of the literature on 15th October 2010 by performing a search of Medical Subject Headings (MeSH) on PubMed using the words sorafenib, sunitinib, bevacizumab, everolimus, pazopanib, or temsirolimus combined with the MeSH term kidney neoplasms. Consideration for inclusion was given to articles providing data concerning (1) incidence and grading and (2) management of targeted therapy-related toxic effects. A separate search was conducted on PubMed to retrieve meta-analyses using each drug name and the word meta-analysis. Evidence synthesis: Hypertension, fatigue, bone marrow toxicity, skin toxicity, and gastrointestinal side-effects are common with the six targeted agents. Everolimus and temsirolimus are associated with immunosuppression, metabolic alterations, and interstitial pneumonitis, while sunitinib is associated with hypothyroidism. Recommendations for treating these conditions usually follow those for the general population because of the lack of experimental data in this setting (eg, for management of sunitinib-induced hypertension). Conclusions: The treating oncologist should try to manage side-effects associated with targeted therapy using supportive and pharmacologic interventions. Severe toxicity requires external specialist consultation and treatment suspension and/or dose reduction. Experimental data about the management of targeted therapy-related toxicity in mRCC is lacking and required in this setting.

KW - Metastatic renal cell cancer

KW - Targeted agents

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=79952282127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952282127&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2011.01.002

DO - 10.1016/j.eururo.2011.01.002

M3 - Article

C2 - 21277078

AN - SCOPUS:79952282127

VL - 59

SP - 526

EP - 540

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -